Tectonic Therapeutic, Inc., a clinical stage biotechnology company specializing in therapeutic proteins and antibodies that target G-protein coupled receptors (GPCRs), has announced its inclusion in ...

WATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (TECX) (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of ...

KIVU-107 is the first PTK7-targeting ADC with a DAR4 exatecan payload, engineered for exceptional stability and highly selective on-tumor delivery.Preclinical data demonstrate deeper and durable ...

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, ...

Despite the approval of numerous antibody-drug conjugates (ADCs), their therapeutic index remains limited by off-target toxicity resulting from linker instability. To address this challenge, the ...

BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a target ...

Valink's bsADC technology aims to address key limitations of current ADCs by integrating novel targeting strategies with improved payload delivery. The company is also exploring complementary ...

Tectonic Therapeutic (NASDAQ:TECX) has been added to the broad-market Russell 3000 Index as part of the 2025 Russell US Indexes annual reconstitution. The addition is effective after the open of US ...